摘要
目的评价2018年中国发布的临床实践指南中有关利益冲突和经济学证据的情况,并与2017年进行比较,以期了解指南制定变化情况,为完善我国临床实践指南的制定/修订提供参考。方法计算机检索中国知网、万方数据库及中国生物医学文献数据库,检索2018年我国发布的临床实践指南,检索时间为2018年1月1日至2018年12月31日。由2名研究者独立筛选文献、提取纳入指南的利益冲突声明与是否关注经济学证据等相关信息后,使用Microsoft Excel 2019软件进行统计分析。结果共纳入临床实践指南92部,其中23部指南(25.00%)声明了利益冲突,25部(27.17%)报告了资金来源,22部(23.91%)报道了经济学证据,且该报道的指南中有一半都有国家重大或重点专项支持(50.00%)。而2017年中国发布的53部临床实践指南中,有26.42%声明利益冲突,18.87%报告资金来源,11.32%提及经济学证据。结论相较于2017年,2018年我国加大了对临床实践指南制定资金投入的力度,在指南经济学证据方面的关注也有所提高,但是对于指南中利益冲突的声明报告和确切的经济学证据仍然很低。因此,进一步推进和完善我国临床实践指南对利益冲突的声明与经济学证据的关注,使我国临床实践指南制定更加客观、透明和独立是必要的。
Objectives To evaluate the status of conflict of interest and economic evidence in Chinese clinical practice guidelines published in 2018,and compare with the relevant content guidelines published in 2017.In order to find the changes in guidelines development and also provide implications for guidelines in China.Methods The CNKI,WanFang Data and CBM were searched to collect clinical practice guidelines published in China in 2018 from January 1st to December 31st.Two researchers independently selected literature,extracted relevant information such as statements of conflict of interest and economic evidences;then,the analysis was performed by using the Microsoft Excel 2019 software.Results A total of 92 clinical practice guidelines were included,in which 23(25.00%)disclosed conflict of interest,25(27.17%)stated sources of funding,and 22(23.91%)reported economic evidence,and half of the reported guidelines were supported by the National Key Research and Development Plan or Science and Technology Major Project of China(50.00%).However,of the 53 clinical practice guide released in 2017,26.42%disclosed conflict of interest,18.87%stated sources of funding,and 11.32%referred to economic evidence.Conclusion Comparative analysis of conflict of interest and economic evidence in Chinese clinical practice guidelines published in 2017-2018,with the increase of financial investment in the development of clinical practice guidelines in China,the attention to economic evidence has also increased,while,we found that the disclosed conflict of interest in the guidelines and the exact economic evidence are still very low.Therefore,we should further promote the report of conflict of interest statement and the generation of economic evidence in our clinical practice guidelines,which will make our guidelines more objective,transparent and independent.
作者
王彦博
王强
赵明娟
贺大林
王云云
Yan-Bo WANG;Qiang WANG;Ming-Juan ZHAO;Da-Lin HE;Yun-Yun WANG(Beijing General Hospital of the Chinese People's Armed Police Force,Beijing 100027,China;Department of Standardization Management,National Center for Medical Service Administration,National Health Commission of the People's Republic of China,Beijing 100044,China;Center for Evidence-Based and Translational medicine of Wuhan University,Wuhan 430071,China;Department of Urology,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China.)
出处
《医学新知》
CAS
2020年第2期139-158,共20页
New Medicine
基金
国家重点研发计划专项课题(2016YFC0106303)
国家卫健委医管中心委托课题([2019]099号)
陕西省重点研发计划项目(2017ZDCXL-SF-01-04-02)。
关键词
临床实践指南
利益冲突
经费来源
经济学证据
Clinical practice guidelines
Conflict of interest
Financial resources
Economic evidence
